There will be a plethora of indications for lenz once it is approved and becomes known to the medical community. Add to that HGEN005 for eosinophilic disorders (esophagitis, gastritis, colitis, leukemia, Hodgkin's disease), and ifabotuzumab, for solid tumors, plus partnership interest already for asthma and arthritis, we could have a very robust pipeline, and we will likely show a more dramatic increase in growth than the big players.
Market Data 
Markets 
AI
